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Background: Post-translational modifications (PTMs) of histones and other proteins are perturbed in tumours. For
example, reduced levels of acetylated H4K16 and trimethylated H4K20 are associated with high tumour grade and
poor survival in breast cancer. Drug-like molecules that can reprogram selected histone PTMs in tumour cells are
therefore of interest as potential cancer chemopreventive agents. In this study we assessed the effects of the
phytocompounds garcinol and curcumin on histone and p53 modification in cancer cells, focussing on the breast
tumour cell line MCF7.
Methods: Cell viability/proliferation assays, cell cycle analysis by flow cytometry, immunodetection of specific
histone and p53 acetylation marks, western blotting, siRNA and RT-qPCR.
Results: Although treatment with curcumin, garcinol or the garcinol derivative LTK-14 hampered MCF7 cell
proliferation, differential effects of these compounds on histone modifications were observed. Garcinol treatment
resulted in a strong reduction in H3K18 acetylation, which is required for S phase progression. Similar effects of
garcinol on H3K18 acetylation were observed in the osteosarcoma cells lines U2OS and SaOS2. In contrast, global
levels of acetylated H4K16 and trimethylated H4K20 in MCF7 cells were elevated after garcinol treatment. This was
accompanied by upregulation of DNA damage signalling markers such as γH2A.X, H3K56Ac, p53 and TIP60. In
contrast, exposure of MCF7 cells to curcumin resulted in increased global levels of acetylated H3K18 and H4K16,
and was less effective in inducing DNA damage markers. In addition to its effects on histone modifications, garcinol
was found to block CBP/p300-mediated acetylation of the C-terminal activation domain of p53, but resulted in
enhanced acetylation of p53K120, and accumulation of p53 in the cytoplasmic compartment. Finally, we show that
the elevation of H4K20Me3 levels by garcinol correlated with increased expression of SUV420H2, and was
prevented by siRNA targeting of SUV420H2.
Conclusion: In summary, although garcinol and curcumin can both inhibit histone acetyltransferase activities, our
results show that these compounds have differential effects on cancer cells in culture. Garcinol treatment alters
expression of chromatin modifying enzymes in MCF7 cells, resulting in reprogramming of key histone and p53
PTMs and growth arrest, underscoring its potential as a cancer chemopreventive agent.
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Enzymes that modify chromatin and associated proteins
by the addition or removal of acetyl or methyl groups
play a key role in genome regulation [1]. These and
other PTMs generate a combinatorial histone code that
demarcates chromatin regions for transcription activa-
tion or repression [2]. Histone PTMs are also critical for
other genomic functions, such as DNA replication and
induction of repair mechanisms at sites of DNA damage
[3]. Histone modifications act as signals that are ‘read’
by sensory proteins containing bromodomains, PHD
fingers and other domains, many of which function as
coregulators of DNA-binding transcription factors [4].
While some core histone PTMs (H3K9Ac, H3K18Ac,
H3K27Ac, H3K4Me3) are commonly associated with
active genes, others (H3K9Me2/3 and H4K20Me3) are
more usually indicators of repressed genes and hetero-
chromatin [1,2]. Specific histone PTMs such as phospho-
S139H2AX (known as γH2A.X) are upregulated by DNA
damage signalling, and are necessary for DNA repair
[3,5]. Not surprisingly, dramatic changes in global his-
tone PTMs are observed in cancer, such as the observed
reduction of H4K16Ac and H4K20Me3 levels in cancer
cell lines, described as hallmarks of cancer [6]. This was
recently confirmed in tissue microarray studies using
large numbers of breast and prostate tumours [7-10].
Interestingly, H4K16Ac and H4K20Me3 are also impli-
cated in DNA damage checkpoints [11,12] which are dis-
rupted in cancer cells. Thus, drug-like molecules that
target chromatin modifying enzymes to reprogram
selected histone PTMs in tumour cells may have poten-
tial as cancer chemopreventive agents.
A number of natural and synthetic molecules that in-
hibit histone acetyltransferase (HAT) or histone deace-
tylase (HDAC) activities have been described. HDAC
inhibitors have shown promise in clinical trials as antic-
ancer therapies, especially when used in combination
with other chemotherapies. Less is known regarding the
in vivo effects of molecules that can inhibit lysine acet-
yltransferase activity in vitro. Natural products that can
block the activity of histone acetyltransferases in vitro
have been isolated from plants [13-15]. Curcumin
(diferuloylmethane) is derived from the turmeric plant
Curcuma longa and inhibits CBP/p300 acetyltransferase
activity in vitro, whereas PCAF appears insensitive to
this compound at concentrations that inhibit p300 [16].
Garcinol is a polyisoprenylated benzophenone present
in Garcinia indica fruit rind that also inhibits both
CBP/p300 and PCAF HAT activities [17]. In this study
we report that garcinol treatment blocks MCF7 cell
proliferation, which is accompanied by induction of
DNA damage repair markers and altered expression of
selected histone/p53 modifying enzymes. This results in
reprogramming of selected histone and p53 PTMs, andin particular can reverse the loss of H4K20Me3 in
tumour cell lines. Our results provide insight into the
biological effects of garcinol in altering histones and p53
PTMs in cancer cells, thus underscoring its potential as a
lead for the development of new anticancer agents.
Methods
Acetyltransferase inhibitors
Curcumin was purchased from Sigma (C-1386). Garcinol
was extracted as described previously [17], and LTK14
was synthesised from garcinol as previously described
[18]. Inhibitor compounds were dissolved in DMSO (gar-
cinol compounds) or ethanol (curcumin).
Cell culture
The breast cancer cell line MCF7, and the osteosarcoma
cell lines U2OS and SaOS2 were maintained in Dulbec-
co’s Modified Eagle Medium (DMEM) supplemented
with 10% foetal calf serum (FCS) and 2 mM glutamine
at 37°C in 5% CO2.
Cell viability/proliferation assays
Viable cells were quantified by a standard MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-di phenyltetrazolium bromide)
reduction assay. Cell-mediated reduction of MTT was
determined by reading absorbance at 550 nm. To meas-
ure the effects of curcumin, garcinol and LTK14 on cell
viability and proliferation, MCF7 cells were seeded into
96-well microtitre plates at a density of 5 × 103 cells/per
well and allowed to adhere overnight. The initial density
of viable cells prior to addition of inhibitors (denoted as
time t=0) was determined in a control plate. Inhibitors
were prepared immediately before use and added to test
wells at the following concentrations (0, 2, 8, 15, 20 μM)
at time zero. After addition of inhibitors or vehicle, cells
were cultured for a further 24 hrs before measurement
of MTT activities. Data were presented as the average of
5 replicates per condition.
Western blots and immunocytochemistry
For western blotting and immuno-cytochemistry cells
were cultured in DMEM supplemented with 10% FCS
and 2 mM glutamine at 37°C in 5% CO2, in the pres-
ence or absence of HAT inhibitors for 24 hours. His-
tones were acid extracted as described [19] for use in
western blotting. For immunocytochemical detection of
specific proteins or PTMs, cells were plated onto cover-
slips in 24 well plates for 24 hours. Following incuba-
tion with the inhibitors or vehicle, the cells were fixed
in 4% paraformaldehyde and permeabilised using 0.2% Tri-
ton X-100 followed by a PBS wash, blocking in 3% BSA,
and addition of primary antibodies as follows: pan acetyl
H3 1:100, pan acetyl H4 1:100, Phospho-Ser139 H2A.X
1:75 (Upstate); H4K16Ac 1:200 (Chemicon); H3K9Ac
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p53K120Ac 1:100, p53K386Ac 1:200, p53K373/382Ac
1:100 (Abcam); p53(D01) 1:100 (Santa Cruz). After 1 hour
incubation, the cells were washed in PBS and incubated
with an appropriate secondary antibody (1:500 dilution).
Images were captured on a Zeiss LSM510 Meta confocal
microscope.
For western blotting, the above antibodies were used at
a dilution of 1:500. In addition, other primary antibodies
were H3 1:2000 (Santa Cruz); hMOF 1:200, TIP60 1:500
(Genetex); SIRT1 1:100, SUV420H1/H2 1:100, H3K9Me3
1:500 (Abcam) and H3K56Ac 1:500 (Epitomics). Appro-
priate HRP-conjugated secondary antibodies were used
at a dilution of 1:5000 (Santa Cruz).
Flow cytometry
To assess the effects of HAT inhibitors on the cell cycle,
cells were treated with inhibitors or vehicle for 24 hours
as described for growth assays, followed by addition of
1 μM Bromodeoxyuridine (BrdU) for 2 hours prior to
harvesting. Cells were fixed, incubated with propidium
iodide to stain DNA and FITC-conjugated anti-BrdU
antibody 3D4 (BD Pharmingen), and subjected to bivari-
ate flow cytometry as described previously [20]. To
quantify the numbers of cells scoring positive for
immunodetection of histone PTMs or SUV420H2 fol-
lowing exposure to HAT inhibitors, treated cells and
controls were treated with trypsin, washed three times
in PBS and fixed in ice-cold 70% ethanol. The permea-
bilised cells were incubated with primary antibodies
(H4K20Me3 1:100 and SUV420H1/H2 1:100) and ap-
propriate Alexa Fluor-conjugated secondary antibodies,
and DNA labelled using propidium iodide. Cells were
washed and resuspended in PBS for flow cytometric
analysis using a FacsAria (BD Biosciences). The total
number of cell scanning events was limited to 4000.
Appropriate negative controls included unstained cells,
PI only, secondary antibody only.
RNA interference
The following siRNA duplexes were used (Dharmacon
Research); SUV420H2 (on-targetplus SMARTpool L-
018622-02), and nontargeting control siRNA (SMART-
pool D-001810-10). MCF7 cells were transfected with
siRNA (5 nM) using INTERFERin (Polyplus) following
the manufacturer's instructions. At 24 hours post trans-
fection cells were treated with 20 μM garcinol and
western blotting carried out as above for the PTM
H4K20Me3. SUV420H2 transcripts in the siRNA
treated cells were measured by RT-qPCR, which was
carried out as described previously [20] using the following
primers; Fwd 5’cgtgtccactcgtgcttg-3’; Rev 5’ctcagcagcccct
catct-3. GAPDH transcript levels were used as the
reference gene.Results
Acetyltransferase inhibitors arrest MCF7 cell proliferation
We assessed the effects of the acetyltransferase inhibi-
tors curcumin and garcinol on proliferation of MCF7
cells in culture. Range finding experiments showed that
concentrations above 20 μM of either compound were
cytotoxic to MCF7 cells, inducing loss of adherence
and cell lysis after 24 h exposure (data not shown).
Thus, to facilitate the correlation of any antiprolifera-
tive effects with changes in histone modifications, cell
proliferation/viability assays were performed using sub-
cytotoxic concentrations of the HAT inhibitors. MCF7
cells were seeded at a density of 5 × 103 cells/per well
and allowed to adhere to plates overnight. MTT assays
were performed to measure initial density of viable cells,
and the change in cell viability/proliferation after culture
for 24 h in the presence of a dose range (2-20 μM) of inhi-
bitors or controls. The initial O.D. 550 nm readings (t=0)
was 1.07 (shown as ‘initial density’ in Figure 1A) and after
24 hrs the control (vehicle-treated) cells showed an in-
crease to an average reading of 1.67 O.D. units, indica-
tive of an increase in viable cells due to proliferation. As
shown in Figure 1A, in comparison to vehicle, curcumin
had a stimulatory effect on the growth of MCF7 cells at
the lowest dose (2 μM), but hampered cell proliferation
at 20 μM. Inhibition of MCF7 cell growth by garcinol
and LTK-14 was observed to be more potent, with a
complete block of growth observed at 20 μM (Figure 1A).
Similar results were obtained using U2OS cells (data not
shown).
To confirm the observed effect of HAT inhibitor
compounds on MCF7 cell growth, cell cycle analyses
were performed using bivariate flow cytometry. As
shown in Figure 1B, MCF7 cells exposed to garcinol
(10 μM) for 24 hours showed a dramatic reduction in
the numbers of actively replicating cells (S phase) com-
pared to controls. This was accompanied by a concomi-
tant increase in the G1 population, consistent with
reduced proliferation and G1 arrest. Similar results
were obtained using the recently described garcinol de-
rivative 14-methoxy-isogarcinol (LTK-14) (Figure 1B)
[18]. Thus, at subcytotoxic concentrations, garcinol
compounds block the ability of MCF7 cells to success-
fully replicate their DNA.
Exposure of MCF7 cells to curcumin for 24 hours also
resulted in a dose-dependent reduction in the proportion
of cells entering S phase, as indicated in Figure 1C. In
contrast to garcinol compounds, curcumin-treated
MCF7 cells showed an increase of cells arrested in G2/M
(a 4–fold increase over control after 24 hrs), (Figure 1C).
Neither inhibitor induced a substantial increase in the
sub-G1 population at the concentrations used, indicating
that cells did not undergo apoptosis or cell death during
the course of the experiment.
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Figure 1 Curcumin, garcinol and LTK-14 impede MCF7 cell proliferation. (A) MCF7 cells were seeded at a density of approximately 5 × 103
cells per well in microtitre plates and allowed to adhere overnight. The initial cell density was determined in a control plate prior to addition of
curcumin, garcinol or LTK-14 at the indicated concentrations, or vehicle. After 24 hours, the change in the number of viable cells was estimated
using MTT assays (see Methods). The data shown are the means of 5 replicates ± standard deviations. (B) Cell cycle analyses of MCF7 cells after
24 hours in culture in the presence of garcinol or LTK14 (10 μM) or vehicle control. The bar charts show a representative experiment indicating the
percentage of cells in G1, S or G2/M phases, and the subG1 population as determined by BrdU incorporation and propidium iodide staining.
(C) Cell cycle analyses of MCF7 cells after 24 hours culture in the presence of curcumin (10 μM or 20 μM) or vehicle control, as described in (B).
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We next compared the effects of curcumin and garcinol
on bulk histone acetylation levels in proliferating MCF7
cells. Cells were treated with curcumin or garcinol at
two sublethal doses (10 μM and 20 μM) for 24 hours,
fixed and subjected to immunocytochemical staining
with antibodies to detect pan-acetylated histones H3 or
H4. As shown in Figure 2A, acetylated H3 was readily
detected in the nuclei of controls, but stain intensity was
reduced after exposure to curcumin, garcinol or LTK14,
indicating H3 hypoacetylation, consistent with previous
reports [18]. Similarly, acetyl-H4 staining appeared to
decrease after exposure to 10 μM of the HAT inhibitors,
but surprisingly was detected at similar intensity as con-
trol at the higher doses (20 μM) of curcumin or garcinol
(Figure 2A). This unexpected effect appears to indicate
differential and dose-dependent effects of these com-
pounds on histone modifications in MCF7 cells.To explore this further we next investigated how the
acetylation status of specific histone N-terminal lysines
is affected by HAT inhibitor treatments. Proliferating
MCF7 cells were treated with inhibitor compounds as
before, and assessed by immunocytochemistry and
western blotting. Acetylation of H3K18, which is a
substrate of CBP/p300 [22] was not inhibited by treat-
ment with curcumin (up to a concentration of 20 μM)
(Figure 2B&D). In contrast, garcinol treatment of MCF7
cells resulted in reduced staining with the H3K18Ac anti-
body (Figure 2B) and decreased detection of H3K18Ac
by western blotting as confirmed by densitometry ana-
lysis (Figure 2D). In contrast, bulk levels of H3K9Ac in
MCF7 cells were not altered following exposure to cur-
cumin or garcinol (Figure 2B&D). Garcinol also reduced
H3K18 acetylation in the osteosarcoma cell lines, U2OS
and SaOS2, whereas curcumin treatment resulted in
increased detection of H3K18Ac (Figure 2E). Thus, inhib-
ition of CBP/p300, or other HATs required for progression
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Figure 2 Reprogramming of global histone modifications by garcinol and curcumin. (A) Nuclear staining of MCF7 breast cancer cells with
antibodies detecting pan acetyl H3 (top panels) or pan acetyl H4 (bottom panels). Control shows typical staining in the absence of inhibitors
(vehicle only), and the effect of treatment with HAT inhibitors at the indicated concentrations are also shown. Scalebar: 10 μm. (B&C)
Immunostaining of MCF7 cells following treatment with the indicated concentrations of curcumin or garcinol for 24 hours. Vehicle control is also
shown. Histone PTM-specific antibodies were used to reveal H3K18Ac, H4K16Ac and H3K9Ac levels in response to treatment. Scalebar: 10μm. (D)
Western blots on whole cell extracts of MCF7 cells. Cell extracts were prepared following 24 hours culture in the presence of HAT inhibitors (or
vehicle control) at the indicated concentrations. Specific antibodies were used to detect bulk levels of H3K18Ac, H4K16Ac and H3K9Ac.
Densitometry measurements were performed using Image J software [21]. The level of each histone PTM in controls (vehicle only, normalised to
a loading control) was set to 1. (E) Western blots showing bulk levels of H3K18Ac in whole cell extracts of U2OS and SaOS2 osteosarcoma cells
following exposure to 10 μM or 20 μM curcumin or garcinol (as indicated in increasing scale). Actin loading controls are also shown, and the
data were quantified by Image J as in (D).
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induced by garcinol, whereas curcumin-induced growth ar-
rest appears to involve a distinct mechanism.
In common with other cancer cell lines [6] and breast
tumours [7], MCF7 cells exhibit low levels of acetylated
H4K16 by immunofluorescence staining (Figure 2B&C).
However, bulk levels of H4K16Ac were increased after
exposure to curcumin or garcinol as observed by im-
munofluorescence (Figure 2B&C) and western blotting
(Figure 2D) consistent with the moderate increase in
pan-acetyl H4 levels (Figure 2A). These results indicate
that selected H3 and H4 PTMs are differentially affected
by curcumin and garcinol.
DNA damage signaling pathways are induced by garcinol
The failure of garcinol-treated cells to complete S-phase,
coupled with loss of H3K18 acetylation and enhanced
acetylation of H4K16 prompted us to compare DNA
damage signaling markers in HAT inhibitor-treated or
control MCF7 cells. As shown in Figure 3A, curcumin
and garcinol induced a dose-dependent increase in the
number and intensity of nuclear γH2A.X foci, consistent
with replication stress-associated DNA damage [23].
This was confirmed by western blotting, with a strong
increase in γH2A.X phosphorylation observed after ex-
posure to garcinol (Figure 3B). Garcinol also increased
the levels of another DNA damage associated histone
PTM, i.e. H3K56Ac (Figure 3B). Thus, inhibition of cell
proliferation by garcinol is accompanied by a DNA dam-
age signaling response in MCF7 cells.
Garcinol alters expression and acetylation of tumour
suppressor p53
The transcription factor p53 is an important regulator of
cell fate decisions that also shows enhanced expression
in response to DNA damage. Western blotting revealed
a strong induction of p53 expression in MCF7 cells trea-
ted with garcinol (Figure 3D). Like histones, p53 func-
tion is regulated by lysine acetylation, which impacts on
its function in transcription, DNA damage checkpoints
and cell fate decisions. Acetylation of lysines in the
C-terminal activation domain of p53 (K370, K372,
K373, K381, K382) is mediated by CBP/p300 and
PCAF and promotes transcriptional activation of p53
target genes [24]. However acetylation of p53 at
K120 within the DNA binding domain can be cata-
lysed by TIP60 in response to DNA damage, and has
been implicated in activation of pro-apoptotic path-
ways both dependent on and independent of tran-
scription [25-27]. Western blots further revealed that
the K120-acetylated form of p53 is readily detected
after garcinol treatment (Figure 3D), and correlated
with increased expression of TIP60 (Figure 3C),
whereas no changes in the levels of other chromatinregulators such as the MYST family HAT, hMOF or the
deacetylase SIRT1, were observed (Figure 3C). Acetyl-
ation of the p53 C-terminal residues K373/382 was
observed to be reduced by garcinol, consistent with its
inhibitory effect on CBP/p300 activity (Figure 3D). Im-
munocytochemical staining revealed that the K120-
acetylated form of p53 was only detected strongly after
garcinol treatment, and was localised to the cytoplasm
(Figure 3E&F). Consistent with the western data,
increased expression of TIP60 was also observed in the
garcinol-treated cells, but not controls (Figure 3E).
Taken together, these results suggest that garcinol has
pleiotropic effects on breast cancer cells. Inhibition of
CBP/p300 activity results in hypoacetylation of both
histone and non-histone targets such as H3K18 and
the C-terminus of p53, consistent with reduced gene
transcription [18]. In addition, garcinol induces repli-
cation stress and DNA damage, resulting in upregula-
tion of the DNA damage signals (γH2A.X, H4K16Ac,
H3K56Ac) and associated proteins (TIP60, p53). The
observed switch in p53 acetylation from C-terminus
to DNA binding domain is consistent with altered
functionality of p53 from transcription activator to
growth arrest/apoptosis.
SUV420H2 mediates H4K20 trimethylation induced by
garcinol
In addition to effects on histone acetylation, we assessed
whether garcinol might affect H4K20 trimethylation, as
this PTM is reduced in cancer cell lines [6]. Immunos-
taining of control (vehicle-treated) cells indicated a rela-
tively low detection level of this PTM in MCF7 cells.
Unexpectedly, a strong dose-dependent enhancement of
H4K20Me3 was detected after exposure of cells to garci-
nol for 24 hours (Figure 4A). Western blotting con-
firmed the garcinol-dependent induction of H4K20Me3,
whereas no dramatic change in the level of trimethylated
H3K9 was detected (Figure 4B). This induction of
H4K20Me3 was unexpected as garcinol is not known to
have direct effects on the activity of lysine methyltrans-
ferases, thus we reasoned that this might be due to an
indirect mechanism, such as by affecting the expression
of chromatin modifying enzymes.
Trimethylation of H4K20 in mammalian cells is cata-
lysed by SUV420H2 [28,29]. As shown in Figure 4C, gar-
cinol treatment of MCF7 cells resulted in a concomitant
increase in both SUV420H2 and H4K20Me3. This was
confirmed by flow cytometry/immunostaining of per-
meabilised cells, which detected an approximate 3-fold
increase in the number of MCF7 cells expressing high
levels of SUV420H2 protein, and an almost 10-fold in-
crease in H4K20Me3 positive cells (Figure 4D). Similar
induction of H4K20Me3 was observed in MCF7 cells
treated with garcinol analogs (data not shown). These
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Figure 4 Garcinol reprograms H4K20 trimethylation by inducing SUV420H2. (A) Immunodetection of H4K20Me3 in MCF7 cells in response
to garcinol treatment. Scalebar: 10 μm. (B) Western blots showing relative levels of H4K20Me3 and H3K9Me3 in acid-extracted histones prepared
from MCF7 cells following treatment for 24 hours with HAT inhibitors at the indicated concentrations or control (DMSO). (C) Western blots
showing induction of SUV420H2 and H4K20Me3 in MCF7 cells in response to garcinol exposure as in (B). (D) Quantitative analysis of the relative
levels of SUV420H2 and H4K20Me3 in MCF7 cells in response to garcinol treatment as detected by flow cytometry. Cells were exposed to
garcinol as in (B) and then fixed and permeabilised before incubation with primary and secondary (543 fluorophore-conjugated) antibodies. The
data shown is the number of cells scoring positive for the indicated antigens from a total of 4000 scanned cells. (E) Relative levels of SUV420H2
transcripts in MCF7 cells at 24 hours post-transfection with siRNA duplexes targeting SUV420H2 (siSUV420H2) or a scramble control (siCTRL) siRNA
mediated knockdown. (F) Western blots on MCF7 cell extracts following siRNA targeting as in (E) followed by exposure to garcinol (20 μM) for a
further 24 hrs. The blot shows detection of H4K20Me3 levels following garcinol treatment in the control or SUV420H2 depleted cells.
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likely to be responsible for the bulk increase in
H4K20Me3 observed after garcinol treatment.
To test this hypothesis, siRNA duplexes were used to
reduce the expression of SUV420H2. As shown in
Figure 4E. SUV420H2 was successfully knocked down
by a specific but not a control siRNA pool as measured
by RT-qPCR. MCF7 cells were transfected with control
or SUV420H2 siRNAs and subsequently treated with
garcinol. Increased levels of H4K20Me3 following treat-
ment with garcinol were observed in the control, how-
ever H4K20Me3 levels were strongly attenuated in the
SUV420H2 knockdown (Figure 4F). Taken together our
results indicate that SUV420H2 expression is induced
after treatment of MCF7 cells with garcinol, and is re-
sponsible for the concomitant increase in trimethylationof H4K20. Thus, we conclude that garcinol treatment
induces changes in expression levels of chromatin modi-
fying enzymes in MCF7 cells, which drive changes in
histone PTMs associated with DNA damage/repair
responses and cell growth arrest.
Discussion
Natural products are an important resource for the
discovery of new leads for cancer therapies. Although
garcinol has been shown to have cancer chemopreven-
tive properties in animal models [30], its biological ac-
tion remains poorly understood. While garcinol may
have pleiotropic effects in cells due to its moderate
antioxidant properties [31], the discovery that it can
directly inhibit histone acetylation by p300 [16,17],
indicates that it may impact directly on global histone
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tumour cells. However, significant gaps remain in our
understanding of the biological effects of garcinol and
related molecules on cell function.
A recent report showed that garcinol can block the
proliferation of MCF7 breast cancer cells in culture [32].
Using concentrations of garcinol in excess of 25 μM, sig-
nificant MCF7 cell apoptosis was observed [32]. In this
study we confirmed the growth inhibitory effects of gar-
cinol against MCF7 cells (Figure 1A), and established
that garcinol is cytotoxic to these cells when used at
concentrations in excess of 20 μM, inducing substantial
loss of cell adherence and cell lysis (data not shown). As
this precludes accurate measurement of the effects of
garcinol on histone PTMs by western blot and immuno-
cytochemical analyses, we performed experiments at
subcytotoxic levels of garcinol (= or < 20 μM) to better
understand its effects on lysine acetylation targets in
MCF7 cells.
The reduced proliferation of MCF7 cells observed in
MTT assays was confirmed by a dramatic decrease in the
number of cells entering S-phase, as detected by BrdU
incorporation in flow cytometry analyses (Figure 1B&C).
However, the data suggested that the biological effects of
curcumin and garcinol/LTK14 in these cells may be
distinct. Curcumin-arrested cells showed an enhanced
accumulation in G2/M, whereas cells treated with
garcinol-related compounds arrested in G1. Similarly,
HEPG2 cells have also been reported to arrest in G2/M
after treatment with curcumin [33]. It is also worth noting
that curcumin differed from garcinol in that it appeared to
stimulate the growth of MCF7 cells at the lowest concen-
tration tested (2 μM) (Figure 1A). This may be consistent
with reports that low levels of curcumin can stimulate pro-
liferation of other cell types, including neural progenitors
[34] and 3T3-L1 preadipocytes [35]. Consistent with its
anti-proliferative effects on a range of other cancer cell
lines, curcumin blocked MCF7 cell growth at higher
doses (10-20 μM) (Figure 1A). These results highlight the
importance of considering the bioavailability of HAT in-
hibitor compounds to select dose ranges that inhibit ra-
ther than promote the growth of malignant cells.
Targeting of histone modifying enzymes is an area of
emerging interest in the development of anticancer
drugs. Pan-inhibitors of deacetylases (HDACs) have
shown promise in preclinical models and have entered
clinical trials. The involvement of CBP, p300, MOZ and
MORF genes in chromosomal translocations associated
with leukaemia [36] suggests that inhibitors of acetyl-
transferase enzymes may also have cancer chemopre-
ventive properties. However, little is known regarding
the biological effects of currently available lysine acetyl-
transferase inhibitors, such as garcinol. Consistent with
previous studies on other cell types [16-18], we haveshown here that treatment of MCF7 cells with curcumin
or garcinol can lead to a dose-dependent reduction in
bulk levels of histone acetylation, as determined using
pan-acetylH3 and pan-acetylH4 antibodies (Figure 2A).
Remarkably however, these compounds were found to
have differential effects on bulk levels of selected PTMs
encountered in histones H3 and H4 (Figures 2, 3, 4).
While curcumin had no obvious negative effect on
H3K18 acetylation at the concentrations tested, garcinol
treatment resulted in H3K18 hypoacetylation in three
cancer cell lines tested (Figure 2B,D&E). In contrast, nei-
ther compound was found to substantially affect H3K9
acetylation (Figure 2B&D). Acetylation of H3K9 has been
shown to be catalysed by GCN5 [37] which is insensitive
to garcinol [17,18]. Interestingly, recent studies have
shown that acetylation of H3K18 by CBP/p300 is
required for the activation of S phase in quiescent fibro-
blast cells [22,38]. Thus, garcinol inhibition of CBP/
p300-mediated acetylation of H3K18 may be a contribu-
tary factor in the failure of MCF7 cells to proceed
through S phase.
Although pan-acetylation of H4 was observed to be
reduced by both curcumin and garcinol at 10 μM, we
noted that at 20 μM this inhibitory effect was not as
clear (Figure 2A). This anomalous result suggested dif-
ferential dose-dependent effects of HAT inhibitors on
H4 acetylation, and highlights the disadvantage of using
pan-acetyl H3/H4 antibodies in that effects on specific
histone PTMs can be masked. However, as shown in
Figure 2B&C, H4K16 acetylation, which is known to be
reduced in cancer cell lines [6], was barely detectable in
control MCF7 cells at the concentration of antibody
used. However, acetylated H4K16 was readily detected
after treatment with curcumin (Figure 2B) or garcinol
(Figure 2B&C). Acetylation of H4K16 is normally estab-
lished by hMOF [39,40] although in conditions of cell
stress other HATs can target this modification, e.g. the
DNA damage-associated TIP60. We did not detect any
change in the expression levels of hMOF after treatment
with garcinol, whereas TIP60 expression appeared to be
elevated (Figure 3C&E). Thus increased expression of
TIP60 or other HATs may account for the increase in
H4K16 acetylation. Although we also attempted to
knock down TIP60 transcripts using siRNA in garcinol-
treated cells, we did not observe a reduction in TIP60
protein levels by western blotting over the time course
of the experiment (data not shown), thus we were un-
able to establish definitively whether TIP60 is respon-
sible for the observed increase in H4K16Ac.
The observed elevation of γH2A.X foci in MCF7
cells exposed to garcinol (Figure 3A&B) is consistent
with an increased incidence of DNA double strand
breaks, likely associated with replicative stress [23].
Interestingly, acetylation of H2A.X by TIP60 has been
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S139 in response to DNA damage [41,42]. TIP60 is also
responsible for acetylation of the DNA binding domain
of p53 at K120 [27]. Our observations that garcinol
induces expression of p53 and TIP60 in MCF7 cells
(Figure 3C-E), accompanied by increased acetylation of
p53K120 and its accumulation in the cytoplasm
(Figure 3E&F), suggests that TIP60 may drive this
switch in p53 function. This is consistent with other
studies revealing that p53K120 is acetylated by TIP60
and that this is important for the apoptotic functions of
p53 in response to DNA damage [27]. It has also been
shown that p53K120Ac is enriched in the cytoplasm
and associated with mitochondria where it impacts on
apoptotic pathways [26]. We conclude that the
garcinol-induced blockade of CBP/p300 inhibits acetyl-
ation of the p53 C-terminus and coupled with upregu-
lation of TIP60 or other HATs, is likely to promote an
acetylation-mediated switch in p53 function.
A surprising observation in our study was that garcinol
also impacts on histone methylation, specifically tri-
methylation of H4K20 (Figure 4A-C). We have shown
that this is due to the induced expression of SUV420H2
(Figure 4C-F), one of the major enzymes targeting H4K20
for multiple methylation. Like H4K16Ac, H4K20Me3 has
been implicated in the repair of DNA damage [11] and cell
senescence [43], both PTMs impact on chromatin struc-
ture [44,45], and a recent study has demonstrated their
interdependence in gene transcription [46]. However, the
consequences of reduced incidence of H4K20Me3 and
H4K16Ac in breast tumours [7] remains to be determined.Conclusion
Our study indicates that in addition to inhibition of
CBP/p300 acetyltransferase activity, garcinol has mul-
tiple biological effects in cancer cells, including the ac-
tivation of DNA damage signaling and the induction of
chromatin regulators such as TIP60 and SUV420H2.
Moreover, we have provided proof of principle that his-
tone PTM signatures associated with cancer can be re-
programmed by the natural product garcinol, a dietary
compound with a traditional use as a chemopreventive
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